Zeramex XT Case Control Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00034449

Enrollment

100

Registered

2024-06-24

Start date

2024-03-13

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periimplant health

Interventions

Group 1: Patients with Zeramex XT Implant Group 2: Control group: Healthy tooth in the same patient

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Zeramex XT implant placed more than 5 years ago Age over 18 Signed informed consent

Exclusion criteria

Exclusion criteria: new immunological disease

Design outcomes

Primary

Measure	Time frame
Evaluation of early inflammation marker (Calprotectin und aMMP8) The evaluation takes place after more than 5 years of the implant being in function / in situ.	—

Secondary

Measure	Time frame
- Evaluation of BOP - Evaluation of Probing depth - Evaluation of IL-1 b (Sulcus fluid) - Evaluation of fVit D3 - Evaluation of Osteocalcin for Vit K2	—

Countries

Germany

Contacts

Public ContactElisabeth Jacobi-Gresser

Oralchirurgisch-zahnärztliche Praxis Dres. Knierim, Igiel & Kollegen

mail@jacobi-gresser.de+49613143388

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026